Clinical Trial News

Recursion Pharmaceuticals announced successful results for its lead drug candidate REC-994, showing it safe and tolerable for cerebral cavernous malformation patients in a Phase 2 study, though likely not satisfying investors closely watching the AI drug developer.

A study finds that semaglutide, used in weight-loss drugs Ozempic and Wegovy, does not increase suicide risk or depression in users without known mental health disorders. The analysis of over 3,500 participants in clinical trials showed no significant difference in suicidal thoughts or behaviors between those taking semaglutide and a placebo, with fewer depressive symptoms reported in the semaglutide group.

Antabio completed Phase 1 trial for MEM-ANT3310, a broad-spectrum antibacterial combination designed to combat antimicrobial resistance in severe hospital infections. The trial showed good tolerability and no serious adverse events, supporting further patient studies.

VAX-31, a 31-valent pneumococcal conjugate vaccine, showed robust immune responses and was well-tolerated in a Phase 1/2 study in adults aged 50 and older, with plans to advance to Phase 3 by mid-2025.

Adaptimmune, a biotech company founded in 2008, has made significant strides in developing T-cell receptor (TCR)-T therapies for cancer. Despite challenges and rocky collaborations with pharmaceutical giants like GSK and Astellas, Adaptimmune achieved a major breakthrough with the FDA approval of its first engineered TCR-T therapy, afami-cel, for treating metastatic or unresectable synovial sarcoma. This approval marks several firsts in the field of cell therapy, offering new hope for patients with rare solid tumors.

BiomX to present positive Phase 1b/2a data for BX004 at ERS Congress 2024, showing favorable safety and efficacy in CF patients with chronic Pseudomonas aeruginosa pulmonary infections.

Clinical Accelerator partners with Tau Medical for the Early Feasibility Study of the Pivot Extend device to treat tricuspid regurgitation in Georgia. The study aims to evaluate safety and efficacy, offering hope for improved outcomes in severe TR cases.

The article presents various studies on antibody drug conjugates, including datopotamab deruxtecan (Dato-DXd) and trastuzumab deruxtecan (T-DXd), in different cancer types such as endometrial, ovarian, breast, lung, and gastric cancers. It also covers studies on immuno-oncology treatments like durvalumab and neoadjuvant strategies, as well as initial results from first-in-human studies of new antibody-drug conjugates like AZD8205 and AZD5335. Additionally, it discusses the role of circulating tumor DNA (ctDNA) dynamics in treatment responses and long-term survival outcomes in various cancer settings.

GSK to present SWIFT-1 and SWIFT-2 phase III trial data for depemokimab, an ultra-long-acting biologic for severe asthma, at the 2024 ERS International Congress, aiming to achieve long-term clinical remission and advance respiratory medicine with 56 abstracts.

Positive immunogenicity and safety data from VLA15-221 Phase 2 study after second booster dose of Lyme disease vaccine candidate VLA15, showing strong immune response and favorable safety profile across all age groups.